Journal Article

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

Zaanan, Aziz, Taieb, Julien, Pallet, Nicolas, Paillaud, Elena, Loriot, Marie-Anne, Narjoz, Céline, Hamdane, Salma, Laprevote, Olivier, Blons, Hélène, Garinet, Simon

2020

Overview

Background Pretherapeutic screening for dihydropyrimidine dehydrogenase (DPD) deficiency is recommended or required prior to the administration of fluoropyrimidine-based chemotherapy. However, the best strategy to identify DPD-deficient patients remains elusive. Methods Among a nationwide cohort of 5886 phenotyped patients with cancer who were screened for DPD deficiency over a 3 years period, we assessed the characteristics of both DPD phenotypes and DPYD genotypes in a subgroup of 3680 patients who had completed the two tests. The extent to which defective allelic variants of DPYD predict DPD activity as estimated by the plasma concentrations of uracil [U] and its product dihydrouracil [UH 2 ] was evaluated. Results When [U] was used to monitor DPD activity, 6.8% of the patients were classified as having DPD deficiency ([U] > 16 ng/ml), while the [UH 2 ]:[U] ratio identified 11.5% of the patients as having DPD deficiency (UH 2 ]:[U] < 10). [U] classified two patients (0.05%) with complete DPD deficiency (> 150 ng/ml), and [UH 2 ]:[U] < 1 identified three patients (0.08%) with a complete DPD deficiency. A defective DPYD variant was present in 4.5% of the patients, and two patients (0.05%) carrying 2 defective variants of DPYD were predicted to have low metabolism. The mutation status of DPYD displayed a very low positive predictive value in identifying individuals with DPD deficiency, although a higher predictive value was observed when [UH 2 ]:[U] was used to measure DPD activity. Whole exon sequencing of the DPYD gene in 111 patients with DPD deficiency and a “wild-type” genotype (based on the four most common variants) identified seven heterozygous carriers of a defective allelic variant. Conclusions Frequent genetic DPYD variants have low performances in predicting partial DPD deficiency when evaluated by [U] alone, and [UH 2 ]:[U] might better reflect the impact of genetic variants on DPD activity. A clinical trial comparing toxicity rates after dose adjustment according to the results of genotyping or phenotyping testing to detect DPD deficiency will provide critical information on the best strategy to identify DPD deficiency.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Cancer Research UK
• Subject: 631/45 / 631/67/69 / Aged / Biomedical and Life Sciences / Biomedicine / Cancer Research / Chemotherapy / Cohort Studies / Cross-Sectional Studies / Dehydrogenases / Dihydropyrimidine Dehydrogenase Deficiency - diagnosis / Dihydropyrimidine Dehydrogenase Deficiency - epidemiology / Dihydropyrimidine Dehydrogenase Deficiency - genetics / Dihydrouracil Dehydrogenase (NADP) - genetics / Dihydrouracil Dehydrogenase (NADP) - metabolism / Drug Resistance / Epidemiology / Female / France - epidemiology / Genetic diversity / Genotype / Genotypes / Genotyping / High-Throughput Nucleotide Sequencing / Humans / Life Sciences / Male / Medication / Middle Aged / Molecular Medicine / Oncology / Pharmaceutical sciences / Phenotype / Phenotypes / Phenotyping / Population studies / Population-based studies / Prevalence / Retrospective Studies / Santé publique et épidémiologie / Toxicity / Uracil / Uracil - analogs & derivatives / Uracil - blood / Uracil - metabolism